These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Striatal hypometabolism in premanifest and manifest Huntington's disease patients. López-Mora DA; Camacho V; Pérez-Pérez J; Martínez-Horta S; Fernández A; Sampedro F; Montes A; Lozano-Martínez GA; Gómez-Anson B; Kulisevsky J; Carrió I Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2183-2189. PubMed ID: 27349245 [TBL] [Abstract][Full Text] [Related]
11. Brain glucose utilization in childhood Huntington's disease studied with positron emission tomography (PET). De Volder A; Bol A; Michel C; Cogneau M; Evrard P; Lyon G; Goffinet AM Brain Dev; 1988; 10(1):47-50. PubMed ID: 2967038 [TBL] [Abstract][Full Text] [Related]
12. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. Mazziotta JC; Phelps ME; Pahl JJ; Huang SC; Baxter LR; Riege WH; Hoffman JM; Kuhl DE; Lanto AB; Wapenski JA N Engl J Med; 1987 Feb; 316(7):357-62. PubMed ID: 2949152 [TBL] [Abstract][Full Text] [Related]
13. Comparison of somatosensory evoked potentials with striatal glucose consumption measured by positron emission tomography in the early diagnosis of Huntington's disease. Kuwert T; Noth J; Scholz D; Schwarz M; Lange HW; Töpper R; Herzog H; Aulich A; Feinendegen LE Mov Disord; 1993; 8(1):98-106. PubMed ID: 8419813 [TBL] [Abstract][Full Text] [Related]
14. The FDG/PET methodology for early detection of disease onset: a statistical model. Clark CM; Ammann W; Martin WR; Ty P; Hayden MR J Cereb Blood Flow Metab; 1991 Mar; 11(2):A96-102. PubMed ID: 1825496 [TBL] [Abstract][Full Text] [Related]
15. A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease. Grafton ST; Mazziotta JC; Pahl JJ; St George-Hyslop P; Haines JL; Gusella J; Hoffman JM; Baxter LR; Phelps ME Ann Neurol; 1990 Nov; 28(5):614-21. PubMed ID: 1979723 [TBL] [Abstract][Full Text] [Related]
16. A primate model of Huntington's disease: functional neural transplantation and CT-guided stereotactic procedures. Schumacher JM; Hantraye P; Brownell AL; Riche D; Madras BK; Davenport PD; Maziere M; Elmaleh DR; Brownell GL; Isacson O Cell Transplant; 1992; 1(4):313-22. PubMed ID: 1344304 [TBL] [Abstract][Full Text] [Related]
17. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Young AB; Penney JB; Starosta-Rubinstein S; Markel DS; Berent S; Giordani B; Ehrenkaufer R; Jewett D; Hichwa R Ann Neurol; 1986 Sep; 20(3):296-303. PubMed ID: 2945510 [TBL] [Abstract][Full Text] [Related]
18. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Grafton ST; Mazziotta JC; Pahl JJ; St George-Hyslop P; Haines JL; Gusella J; Hoffman JM; Baxter LR; Phelps ME Arch Neurol; 1992 Nov; 49(11):1161-7. PubMed ID: 1444883 [TBL] [Abstract][Full Text] [Related]
19. Caudate glucose hypometabolism in a subject carrying an unstable allele of intermediate CAG(33) repeat length in the Huntington's disease gene. Squitieri F; Esmaeilzadeh M; Ciarmiello A; Jankovic J Mov Disord; 2011 Apr; 26(5):925-7. PubMed ID: 21370274 [No Abstract] [Full Text] [Related]
20. Positron emission tomography imaging of regional cerebral glucose metabolism. Alavi A; Dann R; Chawluk J; Alavi J; Kushner M; Reivich M Semin Nucl Med; 1986 Jan; 16(1):2-34. PubMed ID: 2935938 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]